DE69534468D1 - Wachstums-differenzierungsfaktor-11 - Google Patents

Wachstums-differenzierungsfaktor-11

Info

Publication number
DE69534468D1
DE69534468D1 DE69534468T DE69534468T DE69534468D1 DE 69534468 D1 DE69534468 D1 DE 69534468D1 DE 69534468 T DE69534468 T DE 69534468T DE 69534468 T DE69534468 T DE 69534468T DE 69534468 D1 DE69534468 D1 DE 69534468D1
Authority
DE
Germany
Prior art keywords
differentiation factor
growth differentiation
gdf
disclosed
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69534468T
Other languages
English (en)
Other versions
DE69534468T2 (de
Inventor
Se-Jin Lee
Alexandra C Mcpherron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE69534468D1 publication Critical patent/DE69534468D1/de
Application granted granted Critical
Publication of DE69534468T2 publication Critical patent/DE69534468T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69534468T 1994-07-08 1995-07-07 Wachstums-differenzierungsfaktor-11 Expired - Fee Related DE69534468T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US272763 1988-11-17
US27276394A 1994-07-08 1994-07-08
PCT/US1995/008543 WO1996001845A1 (en) 1994-07-08 1995-07-07 Growth differentiation factor-11

Publications (2)

Publication Number Publication Date
DE69534468D1 true DE69534468D1 (de) 2006-02-02
DE69534468T2 DE69534468T2 (de) 2006-07-13

Family

ID=23041174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534468T Expired - Fee Related DE69534468T2 (de) 1994-07-08 1995-07-07 Wachstums-differenzierungsfaktor-11

Country Status (9)

Country Link
US (2) US5914234A (de)
EP (2) EP0776337B1 (de)
JP (1) JPH10502811A (de)
AT (1) ATE305036T1 (de)
CA (1) CA2194660C (de)
DE (1) DE69534468T2 (de)
DK (1) DK0776337T3 (de)
ES (1) ES2251721T3 (de)
WO (1) WO1996001845A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
EP0698094B1 (de) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 zusammensetzungen
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP1988395A1 (de) 1997-05-30 2008-11-05 Curis, Inc. Verfahren zur Beurteilung von Gewebemorphogenese und- aktivität
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
WO1999024057A2 (en) * 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
US6027917A (en) 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
AU2586199A (en) * 1998-02-05 1999-08-23 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
WO2000006716A1 (en) * 1998-07-28 2000-02-10 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
NZ513642A (en) * 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6555374B1 (en) * 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
KR100420798B1 (ko) * 2001-02-10 2004-03-02 (주)알에이싸이언스 펩타이드 벡터
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6798160B2 (en) * 2001-11-02 2004-09-28 Honda Giken Kogyo Kabushiki Kaisha Electric working machine
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
PL375045A1 (en) 2002-02-21 2005-11-14 Wyeth Gasp1: a follistatin domain containing protein
WO2003072714A2 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US20040172667A1 (en) 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
EP1578928B1 (de) * 2002-09-16 2010-03-17 The Johns Hopkins University Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2004245025A1 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
KR20060133961A (ko) 2003-09-12 2006-12-27 와이어쓰 골형성 단백질 전달용의 주사 가능한 인산칼슘 고형 로드및 페이스트
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
WO2005089829A2 (en) 2004-03-10 2005-09-29 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
CA2563374A1 (en) 2004-04-27 2005-12-08 Research Development Foundation Antagonism of tgf-.beta.superfamily receptor signaling
EP2298335B1 (de) 2004-05-25 2014-09-03 Stryker Corporation Verwendung von OP-1 zur Behandlung von Knorpeldefekten
WO2006020884A2 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
BRPI0609439A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de uma resposta imunológica a agentes moduladores de gdf-8
EP1864138A2 (de) * 2005-03-23 2007-12-12 Wyeth Erkennung von gdf-8 modulierenden wirkstoffen
JP5052517B2 (ja) 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
EP1991282B1 (de) 2006-02-09 2013-06-19 BioMimetic Therapeutics, LLC Zusammensetzungen und verfahren zur behandlung von knochen
JP5219359B2 (ja) 2006-02-21 2013-06-26 日東電工株式会社 反射性及び／又は遮光性を有する粘着テープ又はシート、および液晶表示装置
AU2007257208B2 (en) 2006-05-17 2013-05-02 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
JP5484047B2 (ja) 2006-06-30 2014-05-07 バイオミメティック セラピューティクス， エルエルシー 回旋筋腱板傷害を処置するためのｐｄｇｆ−生体マトリックス組成物および方法
US8524265B2 (en) 2006-08-17 2013-09-03 Warsaw Orthopedic, Inc. Medical implant sheets useful for tissue regeneration
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
ES2447516T3 (es) 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8741840B2 (en) 2008-02-13 2014-06-03 Washington University BMP-7 for use in treating neointimal hyperplasia
AU2009236459B2 (en) 2008-04-14 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010030714A2 (en) 2008-09-09 2010-03-18 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
WO2010036978A2 (en) 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
US9150880B2 (en) 2008-09-25 2015-10-06 Proteovec Holding, L.L.C. Vectors for production of antibodies
EP2396025A2 (de) 2009-02-12 2011-12-21 Stryker Corporation Periphere verabreichung von proteinen einschliesslich mitglieder der tgf-beta-superfamilie zur systemischen behandlung von störungen und erkrankungen
CN102369017A (zh) 2009-02-12 2012-03-07 史赛克公司 用于微创系统性递送包含TGF-β超家族成员的蛋白质的组合物和方法
US20120148539A1 (en) 2009-03-24 2012-06-14 Moulay Hicham Alaoui-Ismaili Methods and Compositions for Tissue Engineering
US8609127B2 (en) 2009-04-03 2013-12-17 Warsaw Orthopedic, Inc. Medical implant with bioactive material and method of making the medical implant
WO2010118360A1 (en) 2009-04-09 2010-10-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Production of proteins using transposon-based vectors
BRPI1010587A2 (pt) * 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
ES2836534T3 (es) 2009-06-12 2021-06-25 Acceleron Pharma Inc Proteínas de fusión de ActRIIB-Fc truncadas
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
CN102822197A (zh) 2009-12-22 2012-12-12 史赛克公司 具有降低的免疫原性的bmp-7变体
NZ601559A (en) 2010-02-22 2014-10-31 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US10034945B2 (en) 2012-07-13 2018-07-31 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
EP2912462B1 (de) * 2012-10-24 2019-08-07 Celgene Corporation Biomarker zur verwendung bei der behandlung von anämie
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
US20160120945A1 (en) * 2013-02-15 2016-05-05 The Brigham And Women's Hospital, Inc. Thymic Regeneration
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
WO2015070076A2 (en) * 2013-11-08 2015-05-14 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AU2016297248A1 (en) * 2015-07-22 2018-02-15 Scholar Rock, Inc. GDF11 binding proteins and uses thereof
EP3922645A1 (de) 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latentes-myostatin-antikörper und verwendungen davon
WO2017075055A1 (en) 2015-10-26 2017-05-04 President And Fellows Of Harvard College Reduced and oxidized polysaccharides and methods of use thereof
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
US10287345B2 (en) 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
KR20230169484A (ko) 2016-06-13 2023-12-15 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652951B1 (de) * 1990-06-15 1999-09-01 Carnegie Institution Of Washington GDF-1 und UOG1 Proteine
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
ES2201076T3 (es) * 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
EP0698094B1 (de) * 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 zusammensetzungen

Also Published As

Publication number Publication date
ATE305036T1 (de) 2005-10-15
EP0776337A1 (de) 1997-06-04
CA2194660A1 (en) 1996-01-25
WO1996001845A1 (en) 1996-01-25
DE69534468T2 (de) 2006-07-13
US20020150577A1 (en) 2002-10-17
EP0776337B1 (de) 2005-09-21
EP1574577A2 (de) 2005-09-14
US5914234A (en) 1999-06-22
EP0776337A4 (de) 1998-05-06
EP1574577A3 (de) 2006-06-14
ES2251721T3 (es) 2006-05-01
JPH10502811A (ja) 1998-03-17
CA2194660C (en) 2009-09-29
DK0776337T3 (da) 2005-12-12

Similar Documents

Publication Publication Date Title
DE69534468D1 (de) Wachstums-differenzierungsfaktor-11
EP1559726A3 (de) Wachstumsdifferenzierungsfaktor-10
EP1475440A3 (de) Wachstums-Differentierungsfaktor-3
EP1333035A3 (de) Wachstumsdifferenzierungsfaktor-8
DE69518760T2 (de) Wachstumsdifferenzierungsfaktor-12
AU6215690A (en) Living tissue equivalents
ITMI912432A1 (it) Procedimento e apparecchiatura per la fermentazione di amminoacidi
ATE256182T1 (de) Neuartiges p- selectin ligandenprotein
ATE71658T1 (de) Verfahren zur herstellung von humanlysozym.
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
AU7484791A (en) Method of treating diseases associated with elevated levels of interleukin 1
BG49719A3 (en) Method for preparing of variants chirudine and their use
EP0413329A3 (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
ATE209252T1 (de) Rekombinante d-hydantoinase, verfahren zur herstellung und verwendung
NO931011D0 (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
MY106615A (en) Stabilized leukocyte-interferons.
DE58905768D1 (de) Verfahren zur herstellung von zur rektalen und vaginalen anwendung geeigneten praeparaten biologisch aktiver peptide.
DE59209120D1 (de) Mittel zur Härtung von hornartigen Körperteilen von Säugetieren
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE68915694D1 (de) Verfahren zur Herstellung von verzweigten 1,3-Glykolen und ihren Monoestern.
PT80121B (de) Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
ATE68175T1 (de) Verfahren zur herstellung von l,l oder d,d oder racemat n6 benzyloxycarbonyl 2,6 diaminopimelinsaeuremonoamid.
DE59407086D1 (de) Verfahren zur Herstellung von 3-(p-Fluorphenyl)-2-methylpropionsäure und 3-(p-Fluorphenyl)-2-methylpropionsäurederivaten
DE59407615D1 (de) Verfahren zur Herstellung von Peptiden und Verwendung
DE69323981T2 (de) Verfahren zur Herstellung von optisch aktiven 4-Mercapto-2-pyrrolidionderivat und Zwischenprodukt dafür

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee